Higuchi fractal dimension of the electroencephalogram as a biomarker for early detection of Alzheimer's disease by Al-Nuaimi, A et al.
  
 
Abstract— It is widely accepted that early diagnosis of 
Alzheimer’s disease (AD) makes it possible for patients to gain 
access to appropriate health care services and would facilitate 
the development of new therapies. AD starts many years before 
its clinical manifestations and a biomarker that provides a 
measure of changes in the brain in this period would be useful 
for early diagnosis of AD. Given the rapid increase in the 
number of older people suffering from AD, there is a need for 
an accurate, low-cost and easy to use biomarkers that could be 
used to detect AD in its early stages. Potentially, the 
electroencephalogram (EEG) can play a vital role in this but at 
present, no reliable EEG biomarker exists for early diagnosis of 
AD. The gradual slowing of brain activity caused by AD starts 
from the back of the brain and spreads out towards other 
parts. Consequently, determining the brain regions that are 
first affected by AD may be useful in its early diagnosis. 
Higuchi fractal dimension (HFD) has characteristics which 
make it suited to capturing region-specific neural changes due 
to AD. The aim of this study is to investigate the potential of 
HFD of the EEG as a biomarker which is associated with the 
brain region first affected by AD. Mean HFD value was 
calculated for all channels of EEG signals recorded from 52 
subjects (20-AD and 32-normal). Then, p-values were 
calculated between the two groups (AD and normal) to detect 
EEG channels that have a significant association with AD. k-
nearest neighbor (KNN) algorithm was used to compute the 
distance between AD patients and normal subjects in the 
classification.  Our results show that AD patients have 
significantly lower HFD values in the parietal areas. HFD 
values for channels in these areas were used to discriminate 
between AD and normal subjects with a sensitivity and 
specificity values of 100% and 80%, respectively.   
 
Keywords: Alzheimer’s disease, EEG biomarkers, Higuchi 
fractal dimension, early diagnosis.  
I. INTRODUCTION 
AD is an age-related progressive, neurodegenerative 
disorder that affects cognitive brain functions [1]. The rapid 
increase in the number of people living with AD and other 
forms of dementia due to the aging population represents a 
significant challenge to health and social care systems and to 
society. Currently, there are over 46.8 million individuals 
with dementia worldwide with an annual cost of care 
estimated at US$818 billion. This is projected to reach 74.7 
million by 2030 with an annual cost of US$ 2 trillion ‎[2]. 
However, many dementia sufferers do not receive an early 
diagnosis. It is estimated that more than 50% of people living 
with dementia may not have received timely diagnosis [3]. In 
2011, only 28 million people out of 36 million received a 
diagnosis worldwide [4].  
An early detection of AD will provide an opportunity for 
patients to access appropriate health care services [5,6], 
facilitate the development of effective treatments [7], could 
be useful for identifying people at risk for progression to AD 
[8], and may slow cognitive decline [9]. 
AD starts many years before its clinical manifestations 
[10]. Reliable, accurate, low-cost, and easy to implement AD 
biomarkers that can be used to diagnose AD at preclinical 
stages could be very useful in the care for AD and may assist 
in the development of new treatments.  
Potentially, EEG can play a vital role in the early 
detection of AD [5,6,7,11,12]. Damage to nerve 
cells/pathways in the brain due to AD causes changes in the 
information-processing activity of the brain. These changes 
are thought to be reflected in the information content of the 
EEG ‎[5]. The changes can be quantified and used as a 
biomarker to detect the evolution of AD [13]. The utility of 
EEG to detect brain signal changes even in the 
presymptomatic stage of the disease has been demonstrated 
[13]. EEG is non-invasive, low-cost, has a high temporal 
resolution and provides valuable information about brain 
dynamics in AD ‎[5,6,11]. Moreover, EEG biomarkers can be 
used as the first line of diagnosis to complement other more 
expensive approaches such as neuroimaging (e.g. MRI) [7]. 
The gradual slowing of brain wave activity caused by AD 
starts from the back of the brain and spreads out towards 
other parts during the preclinical stages [6,8,14,15].  
Detecting the brain region that is affected first by AD may be 
useful in its early diagnosis. HFD is a fast computational 
method that can track the changes in a biosignal from a 
measure of its complexity [16,17] and is suited for capturing 
region-specific neural changes due to AD [18]. In addition, it 
has been shown to be an efficient method for discriminating 
between AD patients and normal subjects [13, 18]. Thus, 
HFD of the EEG is potentially a good biomarker for 
determining the regions of the brain that are thought to be 
firstly affected by AD. Smits et al [18] have used HFD for 
AD detection, but not to track changes in the brain due to AD 
or to identify those at high risk of AD. 
In this study, we have used HFD to derive an EEG-based 
biomarker of AD which is then used to determine the region 
of the brain affected first by AD, and to discriminate between 
AD patients and normal subjects. Determining the brain 
regions thought to be affected first by AD based on EEG 
analysis may be useful in early diagnosis of AD. It may also 
be helpful in the development of a tool that could be used to 
identify people at high risk of AD. Our results show that AD 
patients have significantly lower mean HFD values in the 
parietal area. In addition, the HFD biomarker has sensitivity 
and specificity values of 100% and 80%, respectively, in 
distinguishing between AD patients and healthy subjects.  
The paper is arranged as follows. In Section II, the 
materials (including the datasets and EEG recordings) are 
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described. In Section III, the methodology used in the study 
is described. Section IV presents the results and Section V 
concludes the paper. 
II. MATERIALS 
This study was based on EEG data that was recorded 
from 52 volunteers. All the volunteers underwent a strict 
protocol based on normal hospital practices at Derriford 
Hospital, Plymouth, UK [11]. The EEG recordings include 
several states such as hyperventilation, awake, drowsy and 
alert, with periods of eyes closed and open. For storage 
reasons, the sampling rate was reduced from 256Hz to 128Hz 
by averaging two adjacent samples. The duration of each 
EEG signal is 4 minutes. Fig. 1 shows the channel locations 
using a 10–20 system.  
 
Figure 1.  International 10–20 system. 
The EEG dataset was divided into two sub-datasets (A 
and B). The sub-dataset A includes 11 age-matched subjects 
over 65 years old (3 AD, and 8 normal) and has normal EEGs 
as confirmed by a consultant clinical neurophysiologist. The 
sub-dataset A was recorded using the traditional 10-20 
system in a Common Reference Montage by using the 
average of all channels as a reference and the EEG signals 
were converted to Common Average and Bipolar Montages 
using software. The sub-dataset B includes 41 subjects who 
were not perfectly age-matched, 24 subjects were normal (10 
males and 14 females) have mean age 69.4±11.5 years (from 
40 to 84 years), and 17 were probable AD patients (9 male 
and 8 female) have mean age 77.6±10.0 years (from 50 to 93 
years).  All patients were referred to the EEG department of 
Derriford hospital from a specialist memory clinic. A battery 
of psychometric tests (including the MMSE [19], Rey 
Auditory Verbal Learning Test [20], Benton Visual Retention 
Test [21], and memory recall tests [22]) was performed on all 
patients at the memory clinic. The classification of subjects 
with dementia was based on the working diagnosis provided 
by the specialist memory clinic. All healthy volunteers and 
AD patients had their EEG confirmed by a consultant clinical 
neurophysiologist at the hospital as normal and probable mild 
AD respectively [11]. 
III. METHODOLOGY 
Fractal dimension provides a measure of the complexity 
of time series such as the EEG. HFD is a fast nonlinear 
computational method for obtaining the fractal dimension of 
time series signals [16,17,23] even when very few data points 
are available [16]. HFD provides a more accurate measure of 
the complexity of signals compared to other methods (e.g. 
Maragos and Sun, Katz and Petrosian) [16,24,25]. 
To compute the HFD [16,17,18] of an N-sample data 
sequence x(1), x(2), ..., x(N), the data set  is divided into a  k-
length sub-data set  as, 
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The mean of Lm(k) is computed to find the HFD as, 
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The value of HFD of the EEG begins to decrease around 
the age of 60 years [18]. However, the reduction is more 
pronounced in AD patients compared to normal elderly 
people. HFD has been shown to be sensitive to neuronal 
dysfunction [26] and so may be used to identify areas of the 
brain that is affected first by AD. This makes it possible to 
use it to capture region-specific neural changes due to AD. 
 In our approach, the process of deriving the HFD EEG 
biomarker was divided into training and testing phases. In the 
training phase, 39 subjects were selected randomly from 
dataset B (15 AD, and 24 normal). Only subjects from dataset 
B were used in the training phase because of its larger size 
which meant that it has more diversity and covered most of 
the problem space. In the testing phase, 13 subjects were 
selected randomly (2 AD from dataset B, 3 AD and 8 normal 
from dataset A). 
HFD was computed for each EEG channel. As shown in 
Fig. 2, the feature set of each subject was created by 
combining their HFD values (HFDn.1, HFDn.2, …, HFDn.21) 
based on the channel number, where n is the subject’s 
number. To construct the reference feature vector for each 
group (AD or normal), we computed the mean HFD values 
for each EEG channel as shown in Fig. 2, 
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where ch is the channel number, and S is the number of 
subjects in each group (AD or normal). 
Two feature vectors were created, one for AD, and the 
other for normal. Fig. 2 shows the procedure for creating the 
feature set for each subject, and the feature vector for each 
group (AD and normal). 
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Figure 2.  Creating the feature set for each subject, and the reference 
features vector for each group (AD and normal).  
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The HFD values for all 21 channels were computed in the 
training phase and used to construct the two feature vectors 
for AD and normal groups. Each feature vector includes the 
averaged HFD values for the all 21 EEG channels. 
Fig. 3 shows a plot of HFD values for all 21 channels for 
all the subjects in the training dataset. These were used to 
create two feature vectors for AD and normal groups and to 
determine threshold values that separate the two groups. It 
can be seen from the figure that there is little or no difference 
in average HFD values for all 21 channels. This is because 
the changes in the EEG in AD are qualitatively similar to 
those of normal subjects [27]. It may therefore be difficult to 
develop a diagnosis model based on the features of all 21 
channels.  
 
Figure 3.  HFD values of the AD and normal and the threshold between 
them.   
Fig. 4 shows the mean HFD values and the threshold 
values for both AD and normal groups. It can be seen that 
although there is significant overlap in the HFD values for 
some EEG channels, but not for other channels. Channels 
with a high separation of HFD values could be used to 
discriminate between AD patients and normal subjects. For 
example, the average HFD values for channels F3, F4 A1, C4 
T4 and A2 show no discernible difference, but channels Fp1, 
Fp2, Fz, Cz, T5, P3, Pz, P4, T6, O1 and O2 show differences 
between the two groups. It may therefore be possible to 
discriminate between AD and normal based on the average 
HFD values in these channels.  
   
Figure 4.  Mean HFD values for AD and normal groups, and the threshold 
between them. 
Fig. 4 shows the mean HFD values of AD patients are 
lower than in normal subjects. 
To determine the region of the brain that is affected first 
by AD and the most significant EEG channels that may be 
used to discriminate between AD patients and normal 
subjects, the p-values of the mean HFD values of AD patients 
and normal subjects for the all 21 EEG channels were 
analysed using t-tests. The p-value was used as a criterion to 
determine the best EEG channels that can be used in the 
classification. Table I shows the p-values between the two 
groups (AD and normal).  
TABLE I.  P-VALUES BETWEEN AD AND NORMAL GROUPS 
Channel P-values 
Fz 0.028111522 
Cz 0.039124719 
Pz 0.059441060 
P3 0.072958495 
T6 0.096962212 
P4 0.104595362 
T5 0.163009137 
Fp1 0.164677171 
Fp2 0.216162653 
F7 0.328010598 
F8 0.351212252 
C3 0.428339823 
O2 0.548701678 
O1 0.644081467 
A2 0.666513881 
F3 0.687416694 
T4 0.717922825 
T3 0.747577598 
A1 0.828733195 
C4 0.844921141 
F4 0.872691805 
As shown in Fig 5, the mean p-value for each lobe of the 
brain was computed to detect which lobe was mostly affected 
by AD based on HFD analysis. The results show that the 
parietal lobe has the minimum mean p-value compared to the 
other lobes of the brain as shown in Fig. 5. This is consistent 
with the idea that the gradual slowing of the brain wave 
activity caused by AD starts from the back of the brain and 
then spreads out to the other parts over the time [6,8,14,15]. 
Thus, the gradual reduction in the HFD values could be used 
to determine the brain regions that are thought to be  affected 
first by AD and hence subjects at high risk of dementia. 
 
 
Figure 5.  Mean P-values for each lobe of the brain. 
Table I shows that some EEG channels have small p-
values. HFD of such channels may be used to discriminate 
between AD patients and normal subjects. From the analysis 
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of  HFD values channels with p-values of less than 0.1 were 
selected as having high discriminating power in 
distinguishing between AD patients and normal subjects. We 
were also interested in determining the minimum number of  
EEG channels that may be used to discriminate between AD 
patients and normal subject. We selected five EEG channels 
(Fz, Cz, P3, Pz, and T6) that satisfied the threshold for p-
value as features with the potential to discriminate between 
the two groups. The average HFD values from the selected 
channels were used to design a model for AD diagnosis. The 
channel selection was based on the analysis of the average 
HFD values for all the channels for the training EEG dataset. 
Two reference feature vectors were created, one for AD 
patients and the other for normal subjects. Each reference 
feature vector includes the average HFD values for the 
selected channels. 
In the testing phase, HFD values from the selected 
channels (Fz, Cz, P3, Pz, and T6) were computed for each 
unknown subject whose AD status we want to predict. The 
HFD values were computed in the same manner used for 
computing the reference vectors for the two groups of the 
training dataset. The k-nearest neighbor (KNN) algorithm 
[28,29] was used to compute the distances between the 
unknown feature vector extracted from an unseen EEG signal 
and the two reference feature vectors of AD and normal as, 
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where D is the KNN value representing the distance between 
the two classes (x and y), i is the indicator for a known 
subject (class x), and j refers to the unseen subject (class y). 
The norm ||x-y|| was calculated using the Euclidean distance 
measure [29,30]. The Euclidean distance was computed as, 
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where Ej is the Euclidean distance between the extracted 
features for the unseen subject j and the reference feature 
vector, n is the number of channels (n=5), m represents the 
group code (AD or normal), l is the channel number, (HFDl)m 
is the mean HFD value of the reference feature vector, and 
(HFDl)j is the mean HFD value for the unseen subject j. 
The unseen subject is classified as AD if its distance is 
closer to the AD reference feature vector, else it is classified 
as normal. The ability to discriminate between AD patients 
and normal subjects will depend on the proportional distance 
between the two reference feature vectors of AD patients and 
normal subjects. The minimum distance will provide the high 
discrimination rate.    
IV. RESULTS AND DISCUSSIONS 
In this study, we investigated whether HFD biomarker 
could be used to determine the region of the brain that is 
affected first by AD and to discriminate between AD patients 
and normal subjects. We analysed the HFD values for all 
EEG channels. The KNN classifier was used to discriminate 
between the AD patients and normal subjects. 
To detect the most part of the brain that is affected due to 
AD, the p-values between the two groups (AD and normal) 
were computed. The results show the parietal lobe has the 
minimum mean p-value compared with the other brain’s 
lobe. This demonstrates the gradual slowing of the brain 
wave activity caused by AD starts from the back of the brain 
and then spreads out to the other parts over the time. We can 
conclude the gradual reduction in the HFD values that could 
be used to determine the brain regions that are thought to be 
firstly affected by AD and then may be used to detect the 
subjects at high risk of dementia. 
We selected 5 EEG channels (Fz, Cz, P3, Pz, and T6) to 
discriminate between AD patients and normal subjects by 
analysing the mean HFD values for all EEG channels. As 
shown in Table I, these 5 channels have the minimum p-
values (between 0.09 and 0.02).  
AD patients can be characterised by the slowing of the 
brain activity [6]. This slowing is reflected in the EEG signal. 
The results show that the mean HFD values of AD patients 
are lower than in normal subjects as shown in Fig 3. The 
reduction in HFD values is thought to be due to the slowing 
in the EEG as a result of AD and this is in keeping with the 
finding in other studies ‎[5,18,31]. The results of our study are 
consistent with other studies that found that the slowing of 
the EEG is a marker for the subsequent rate of cognitive and 
functional decline in AD patients ‎[5,6,32]. 
The performance of the HFD biomarker was assessed by 
calculating its sensitivity, specificity, accuracy, precision, 
error rate as shown in Table II.   
TABLE II.  PERFORMANCE RESULTS OF  HFD BIOMARKER 
Sensitivity 100.00 % 
Specificity 80.00 % 
Accuracy 84.615 % 
F-measure  75.00 % 
Error rate 0.1538  
Matthew’s correlation coefficient (MCC) was computed 
to measure the quality of the binary classification (AD and 
normal) in machine learning between the actual and 
predicted results [33,34]. The MCC of the HFD was 0.6928. 
The main advantage of a diagnostic test is to utilise it in 
the diagnosis. Sensitivity and specificity did not provide 
clinicians with the probability of the disease in a patient. 
While the probability of the test provides that and this may 
help to diagnose successfully. Therefore, there is a need to 
direct the diagnostic test towards the predictive values. The 
predictive values of the test rely on the prevalence of the 
abnormality in the patients being tested (the prevalence can 
be defined as the probability before the test is performed that 
a subject has the diseases). The ratio of these probabilities 
represents the likelihood ratio (LR). LR can be used to 
estimate the probability of diagnosis by combining the 
sensitivity and specificity in one measurement to produce that 
probability [35,36]. The LR provides the advantage of the 
applied model that was used in the testing [37], the decision 
can be used to compute the probability of abnormality from 
other different probabilities [38], and LR points the 
usefulness of the test for raising certainty about the success of 
the diagnosis [35]. The LR+ and LR- for HFD were 3.6670 
and 0, respectively. A high FPR and FNR will minimize the 
diagnostic performance of the system [39]. FPR and FNR are 
0.272, and 0 for HFD. The positive and negative predictive 
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values (PPV, NPV) are the purified estimates of the same 
probability of subjects to give the correct diagnosis [35,36]. 
The PPV, and NPV for HFD were 0.6000, and 1.0, 
respectively.   
V. CONCLUSION 
 Our results suggest that HFD biomarker is a promising 
biomarker that captures the regions of the brain thought to be  
affected first by AD in its early stages and could be used to 
detect subjects at high risk of dementia. As AD subjects 
have significantly lower HFD values, this provides an 
effective way to discriminate between AD patients and 
normal subjects. Potentially, the slowing of the EEG is a 
marker for the subsequent rate of cognitive and functional 
decline in AD patients. Future work will evaluate the HFD 
biomarker using larger EEG datasets. 
ACKNOWLEDGMENT 
The first author would like to thank The Ministry of 
Higher Education and Scientific Research (MoHESR) - Iraq 
for their financial support. Financial support by the EPSRC 
is also gratefully acknowledged. 
REFERENCES 
[1] E. C. Ifeachor et al., “Biopattern analysis and subject-specific 
diagnosis and care of dementia,” in Engineering in Medicine and 
Biology Society, 2005. IEEE-EMBS 2005. 27th Annual Int. Conf. of 
the, 2006, pp. 2490–2493. 
[2] M. Prince et al., “World Alzheimer Report,” 2015. 
[3] E. Jammeh et al., “Using NHS primary care data to identify 
undiagnosed dementia,” J. Neurol. Neurosurg. Psychiatry, vol. 86, no. 
11, pp. e4–e4, 2015. 
[4] M. Prince et al., World Alzheimer Report 2011: The benefits of early 
diagnosis and intervention. Alzheimer’s Disease International, 2011. 
[5] A. H. Al-nuaimi et al., “Tsallis entropy as a biomarker for detection of 
Alzheimer’s disease,” in Engineering in Medicine and Biology 
Society (EMBC), 2015 37th Annual Int. Conf. of the IEEE, 2015, pp. 
4166–4169. 
[6] A. H. Al-nuaimi et al., “Changes in the EEG amplitude as a biomarker 
for early detection of Alzheimer’s disease,” in Engineering in 
Medicine and Biology Society (EMBC), 2016 IEEE 38th Annual Int. 
Conf. of the, 2016, pp. 993–996. 
[7] D. Ferreira et al., “Electroencephalography is a good complement to 
currently established dementia biomarkers,” Dement. Geriatr. Cogn. 
Disord., vol. 42, no. 1–2, pp. 80–92, 2016. 
[8] D. V Moretti, “Theta and alpha EEG frequency interplay in subjects 
with mild cognitive impairment: evidence from EEG, MRI, and 
SPECT brain modifications,” Front. Aging Neuro., vol.7, p.31, 2015. 
[9] R. A. Sperling et al., “Toward defining the preclinical stages of 
Alzheimer’s disease: Recommendations from the National Inst. on 
Aging-Alzheimer’s Asso. workgroups on diagnostic guidelines for 
AD,” Alzheimer’s Dement., vol.7, no.3, pp.280–292, 2011. 
[10] A. L. Sutton., Ed., Alzheimer Disease Sourcebook, Fifth edit. Detroit: 
Omnigraphics: Peter E. Ruffner, 2011. 
[11] G. Henderson et al., “Development and assessment of methods for 
detecting dementia using the human electroencephalogram,” IEEE 
Trans. Biomed. Eng., vol. 53, no. 8, pp. 1557–1568, 2006. 
[12] D. V. Moretti, “electroencephalography-driven approach to prodromal 
Alzheimer’s disease diagnosis: from biomarker integration to 
network-level comprehension,” Clin. Interv. Aging, vol. 11, p. 897, 
2016. 
[13] B. Dubois et al., “Preclinical Alzheimer’s disease: definition, natural 
history, and diagnostic criteria,” Alzheimer’s Dement., vol. 12, no. 3, 
pp. 292–323, 2016. 
[14] C. Babiloni et al., “Directionality of EEG synchronization in 
Alzheimer’s disease subjects,” Neurobiol. Aging, vol. 30, no. 1, pp. 
93–102, 2009. 
[15] U. A. Khan et al., “Molecular drivers and cortical spread of lateral 
entorhinal cortex dysfunction in preclinical Alzheimer’s disease,” Nat. 
Neurosci., vol. 17, no. 2, pp. 304–311, 2014. 
[16] A. Accardo et al., “Use of the fractal dimension for the analysis of 
electroencephalographic time series,” Biol. Cybern., vol. 77, no. 5, pp. 
339–350, 1997. 
[17] H. Preißl et al.,“Fractal dimensions of short EEG time series in 
humans,” Neurosci. Lett., vol. 225, no. 2, pp. 77–80, 1997. 
[18] F. M. Smits et al., “Electroencephalographic fractal dimension in 
healthy ageing and Alzheimer’s disease,” PLoS One, vol. 11, no. 2, p. 
e0149587, 2016. 
[19] M. F. Folstein et al., “‘Mini-mental state’: a practical method for 
grading the cognitive state of patients for the clinician,” J. Psychiatr. 
Res., vol. 12, no. 3, pp. 189–198, 1975. 
[20] E. S. O. Spreen, A Compendium of Neuropsychological Tests: 
Administration, Norms, and Commentary, 2nd ed. Oxford University 
Press, Inc, February 1998, ISBN 0-19-510019-0. 
[21] A. L. Benton, “Revised Visual Retention Test: Clinical and 
Experimental Applications Psychological Corporation,” New York, 
1974. 
[22] G. A. Talland and M. Ekdahl, “Psychological studies of Korsakoff’s 
psychosis: IV. The rate and mode of forgetting narrative material.,” J. 
Nerv. Ment. Dis., vol. 129, no. 4, pp. 391–404, 1959. 
[23] T. Higuchi, “Approach to an irregular time series on the basis of the 
fractal theory,” Phys. D Nonlinear Phenom., vol. 31, no. 2, pp. 277–
283, 1988. 
[24] R. Esteller et al., “A comparison of fractal dimension algorithms using 
synthetic and experimental data,” in Circuits and Systems, 1999. 
ISCAS’99. Proc. 1999 IEEE Int. Symp. on, 1999, vol. 3, pp. 199–202. 
[25] C. Gómez et al., “Use of the Higuchi’s fractal dimension for the 
analysis of MEG recordings from Alzheimer’s disease patients,” Med. 
Eng. Phys., vol. 31, no. 3, pp. 306–313, 2009. 
[26] F. Zappasodi et al., “Fractal dimension of EEG activity senses 
neuronal impairment in acute stroke,” PLoS One, v.9, no.6, p. 
e100199, 2014. 
[27] G. W. Fenton, “Electrophysiology of Alzheimer’s disease,” Br. Med. 
Bull., vol. 42, no. 1, pp. 29–33, 1986. 
[28] J. P. M. De Sa, Pattern recognition: concepts, methods and 
applications. Springer Science & Business Media, 2012. 
[29] A. N. Papadopoulos, Nearest Neighbor Search:: A Database 
Perspective. Springer Science & Business Media, 2006. 
[30] D. Michie, D. J. Spiegelhalter, and C. C. Taylor, “Machine learning, 
neural and statistical classification,” 1994. 
[31] D. Abásolo et al., “Analysis of regularity in the EEG background 
activity of Alzheimer’s disease patients with Approximate Entropy,” 
Clin. Neurophysiol., vol. 116, no. 8, pp. 1826–1834, 2005. 
[32] J. Jeong, “EEG dynamics in patients with Alzheimer’s disease,” Clin. 
Neurophysiol., vol. 115, no. 7, pp. 1490–1505, 2004. 
[33] S. Raschka, “An Overview of General Performance Metrics of Binary 
Classifier Systems,” arXiv Prepr. arXiv1410.5330, 2014. 
[34] DM Powers, “Evaluation: from precision, recall and F-factor to ROC, 
informedness. markedness correlation”. Technical report, School of 
Informatics and Engineering, Flinders University, Australia; 2007 
[35] D. G. Altman and J. M. Bland, “Statistics Notes: Diagnostic tests 2: 
predictive values,” Bmj, vol. 309, no. 6947, p. 102, 1994. 
[36] A. K. Akobeng, “Understanding diagnostic tests 1: sensitivity, 
specificity and predictive values,” Acta Paediatr., vol. 96, no. 3, pp. 
338–341, 2007. 
[37] A. G. Lalkhen and A. McCluskey, “Clinical tests: sensitivity and 
specificity,” Contin. Educ. anaesthesia, Crit. care pain, vol. 8, no. 6, 
pp. 221–223, 2008. 
[38] J. J. Deeks and D. G. Altman, “Diagnostic tests 4: likelihood ratios,” 
Bmj, vol. 329, no. 7458, pp. 168–169, 2004. 
[39] J. P. A. Ioannidis, R. Tarone, and J. K. McLaughlin, “The false-
positive to false-negative ratio in epidemiologic studies,” 
Epidemiology, vol. 22, no. 4, pp. 450–456, 2011. 
2324
